GlaxoSmithKline: Luke Miels appointed president, global pharmaceuticals
Mr. Miels is currently Executive Vice President of AstraZeneca’s European business and was previously EVP, Global Product and Portfolio Strategy, Global Medical Affairs and Corporate Affairs.
Over the course of his career, Mr. Miels has built highly effective strategic partnerships between R&D and the relevant commercial organisations to develop superior portfolio and product franchises at AstraZeneca, Roche and Sanofi-Aventis.
Mr. Miels has significant international experience having worked and lived in the US, China, Singapore, the UK and continental Europe.
At AstraZeneca, he has helped strengthen the company’s product portfolio, launching Tagrisso in the US, improving growth of the cardiovascular and metabolic portfolios, notably Brilinta, and through business development with investments in companies such as Acerta Pharma and the acquisition of ZS Pharma.
Mr. Miels joined AstraZeneca from Roche, where he was Regional Vice President Asia Pacific for the Pharmaceuticals Division.
Before then, he held roles of increasing seniority at Sanofi-Aventis, including positions in Asia Pacific and the US. He also co-led the US integration of Sanofi and Aventis.
Mr. Miels began his career in 1995 as a Sales Representative and Product Manager with AstraZeneca in Australia.
He holds a BSc in biology from Flinders University in Adelaide and an MBA from the Macquarie University, Sydney. ■
What to read next
LATEST MOVES FROM United Kingdom
- Mallinckrodt Pharmaceuticals elects David Norton to board
- John Lewis Partnership appoints Laura Wade-Gery as director
- 40% of senior executives to leave Reckitt Benckiser
- Oxford Immunotec Global appoints Stefan Linn as COO
- Terra Firma Capital appoints Jerry Patava to board
More inside POST
Elbit demos its unmanned surface vessel Companies